Senior housing is the fastest-growing institutional asset class globally. The clinical risk profile of acquired assets isn't keeping pace.
Memory care assets carry elevated risk of undiagnosed or poorly managed seizures in residents with dementia — risks that remain invisible in standard financial and regulatory reviews. When an adverse event occurs in a portfolio facility after close, and the record shows behavioral episodes that went unrecognized and undocumented, the liability follows the asset. Seagull Health delivers clinical intelligence on this gap before it becomes a post-close problem.
The Market Context
Senior housing investment is accelerating across every major market. US transaction volume reached a decade high in 2025. Welltower alone deployed $6.2 billion in seniors housing investments in Q1 2025 — exceeding its entire 2024 total. Private equity and REITs now represent the majority of acquisition volume.
The assets being acquired carry a clinical risk profile that standard due diligence was not designed to assess. Memory care is the fastest-growing segment of senior housing — and the segment with the highest concentration of dementia residents, the highest seizure prevalence, and the largest gap between what facilities should be documenting and what records show they actually documented.
That gap does not disappear at close. It reprices the asset.
United States
$24B transaction volume — decade high. Welltower: $6.2B in Q1 2025 alone.
Haven Senior Investments / CRE Daily / Senior Housing News
United Kingdom
£2.24B invested YTD through Q3 2025 — up 24.1% year over year.
Cushman & Wakefield
Japan
Healthcare PE growing at 20% CAGR since 2019. ~30% of population aged 65+.
Bain & Company APAC Report
Asia-Pacific
Record healthcare PE deal value in 2025 — exceeding the prior 2021 high by 30%+.
Bain & Company
Europe
Institutional penetration in senior care below 3% in most countries — significant runway.
Real Asset Insight
The Due Diligence Gap
PE and REIT due diligence in senior care is documented to assess financial health, clinical quality metrics, infection control, readmission rates, malpractice insurance history, and regulatory compliance. These are the right categories. They are not the complete picture.
Financial health and revenue cycle analysis
Clinical quality metrics — mortality rates, readmission rates
Infection control protocols and outcomes
Malpractice insurance history and active litigation
Regulatory compliance — CMS survey citations, F-tags
Staffing ratios and HR practices
Technology systems and EHR infrastructure
Whether the facility has a documented seizure recognition protocol for dementia residents
Whether staff have been trained to identify seizure presentations in the absence of convulsive activity
Whether behavioral episodes in the clinical record meet published criteria for seizure presentations requiring escalation
Whether the gap between what the record shows and what the standard of care required constitutes undisclosed liability
The Risk Timeline
The difference between pre-acquisition intelligence and post-close discovery is the difference between a negotiating position and an inherited liability.
Before close, the clinical record is a data asset. Behavioral episode patterns, documentation gaps, and protocol absences are negotiating information — not inherited liability.
After close, the same clinical record is a liability document. The behavioral episodes that weren't evaluated become the evidentiary foundation for standard-of-care claims against the asset you now own.
Where CRISP sits in the timeline
CRISP delivers a clinical intelligence brief on seizure-related risk exposure in a target facility or portfolio before the acquisition closes — giving deal teams the clinical picture that standard due diligence doesn't produce, at a cost that is a rounding error against any deal budget.
Who This Is For
CRISP intelligence is calibrated for investors and deal teams who need clinical risk translated into financial exposure — not a clinical study. If you are evaluating, acquiring, or managing memory care assets, this is your product.
Acquiring or developing memory care and skilled nursing assets. CRISP provides the clinical risk overlay your financial model doesn't include — before the deal closes.
Acquisition and asset management teams evaluating operator clinical quality at scale. CRISP delivers a consistent, literature-grounded risk assessment for every target asset.
Evaluating new investments or monitoring existing portfolio clinical exposure. CRISP scopes to your portfolio size and deal cadence, from a single asset to a multi-facility review.
What Seagull Health Delivers
The DSCA is a structured clinical risk report modeled after pre-acquisition due diligence standards — the same logic environmental reports use to document what's in the ground before a real estate closing, applied to what's in the clinical record before a senior care acquisition. Findings are documented. Investment conclusions are not drawn. Delivered in one business day. Volume pricing for three or more assets.
Six-Section Report Structure
Facility Types Covered
A structured DSCA-based review across existing portfolio assets — identifying which facilities carry elevated seizure-related liability exposure based on dementia census, facility type, documentation patterns, and regulatory record. Each facility receives its own DSCA; the portfolio review aggregates findings across assets. Scoped per engagement.
Investment Committee Deliverables
Clinical Intelligence Included
Built from Operator Reality
CRISP intelligence is created by Russ Barker, MHA — a 25-year nursing home administrator who lived through multiple owner transitions, operated memory care units, and is completing his doctoral dissertation on seizure risk evaluation frameworks in long-term care. The intelligence is designed to strengthen your existing due diligence process on one of the most material undocumented risks in memory care — not to replace your clinical advisors.
The Financial Context
Average nursing home negligence settlements range from $400,000 to $2.36 million. Nuclear verdicts — judgments exceeding $10 million — are normalizing in senior care litigation. The trajectory is not favorable to operators or the investors who own them.
The financing of these claims has also changed. Institutional third-party litigation funders are now actively financing elder care cases, lowering the barrier for plaintiff attorneys to pursue claims that would previously have been cost-prohibitive. The capital that is flowing into senior housing on the investment side is being matched by capital on the plaintiff side.
A clinical intelligence assessment that identifies seizure-related risk exposure before close is not a speculative cost. PE due diligence budgets run 1%–3% of deal value. On a $20 million acquisition, that is $200,000–$600,000. A CRISP brief is a rounding error against that budget — and addresses a risk category the budget does not currently include.
Average nursing home negligence settlement range
Nursing Home Abuse Center / Sokolove Law
Litigation Funding — New Risk Factor
Institutional third-party litigation funders are now actively financing elder care cases. Third-party funding lowers the barrier for plaintiff attorneys to pursue claims against facilities — and the institutional investors who own them. The same clinical record gaps that were previously cost-prohibitive to litigate are now financeable.
Global Scope
Senior housing investment activity is documented across the US, UK, Japan, and Asia-Pacific. The clinical risk gap that CRISP addresses — failure to recognize and document seizure presentations in dementia residents — exists wherever memory care is delivered without formal seizure protocols.
Whether the legal liability exposure and litigation framework that makes this intelligence actionable in the US translates directly to non-US jurisdictions requires local legal analysis not yet conducted. Seagull Health works with organizations across these markets and scopes each engagement accordingly.
Clinical due diligence + litigation liability framework fully applicable. Primary CRISP market. Direct case law context established.
Clinical due diligence applicable. Legal liability framework requires UK legal counsel. Common law jurisdiction — secondary potential confirmed.
Clinical due diligence applicable. Legal and regulatory framework differs from US. Jurisdiction-specific scoping required.
Transaction volume confirmed. Clinical intelligence applicable. Legal liability translation requires local analysis. Engage Seagull Health to scope.
Start an Inquiry
Request a de-identified sample DSCA for one of your current pipeline assets, or schedule a 15-minute call to discuss your deal or portfolio.